Concise Article
MedChemComm
strong support for hydrophobic interactions between one
of the aromatic esters of brartemicin and the side chains of
residues Leu172, Val173, Val194, Phe197, and Phe198 that
together comprise the hydrophobic groove adjacent to the
Ca2+-ion. The size of the aromatic ring is closely matched with
the size of the groove. The second aromatic ester is oriented in
the opposite direction within the binding site in the vicinity of
Arg182 indicating possible π-cation interactions and in the
vicinity of Asp165/Asp183 where polar contacts are possible
(Fig. 3b, c). Overall the calculations suggest a possible position
of the second ester substituent and an overall elongated con-
formation of brartemicin in the binding site. The above men-
tioned interactions can explain the 290-fold increase in bind-
ing affinity of brartemicin compared to α,α-trehalose.
the benzyl-protected α,α-trehalose (50 mg, 0.06 mmol, 1.0
equiv.) and 2,4-bis-IJbenzyloxy)-6-methylbenzoic acid (43 mg,
0.12 mmol, 2.2 equiv.) in dry benzene and this was concen-
trated to dryness. This was repeated three times. The residue
was then dissolved in dry DCM (0.24 mL) in a flame-dried
schlenk flask containing a stirring bar and flushed with Ar.
The mixture was cooled to 0 °C and DCC (0.03 g, 0.14 mmol,
2.4 equiv.) and a catalytic amount of DMAP was added. The
reaction was allowed to reach rt and was stirred overnight
under an argon atmosphere. After 26 h the reaction mixture
was filtered to remove the urea product of DCC. The filtrate
was concentrated in vacuo. Purification of the crude prod-
uct by FC (SiO2, 15 × 2 cm, EtOAc/pentane 1 : 5 → EtOAc/
pentane 1 : 4 → EtOAc/pentane 1 : 2) yielded the diester (62 mg,
0.04 mmol, 71%) as a colorless oil. Rf 0.50 (EtOAc/pentane 1 : 5
Docking of epi-brartemicin (5) and the monoester (4) under
the same conditions as 1 suggests subtle changes in the bound
conformations, which could explain the reduced affinity of
these compounds. Whereas the ensemble of poses found
for brartemicin (Fig. S2a†) show a very well defined binding
mode, the ensembles of poses for both monoester (4) and
epi-brartemicin (Fig. S2b–c†) are much more diffuse suggesting
that key stabilizing interactions are diminished. In both these
structures, the glucose ring in the secondary binding site is
rotated significantly relative to the brartemicin structure. Most
notably, the altered glycosidic configuration in epi-brartemicin
is incompatible with an elongated conformation in the binding
site and key hydrogen bonds are absent. Surprisingly, the
computational studies of the monoester (4) indicate that in this
molecule the aromatic ester occupies an alternative cavity
in close vicinity to the hydrophobic groove (Fig. S2c†). The
reduced interactions in these structures reflect in lower docking
scores in accord with the relative affinities (Table S1, Fig. S4†).
Overall, our experiments and computational studies indicate
that brartemicin and epi-brartemicin constitute a pair of mole-
cules that will allow affinity correlations in future functional
assays. The structural requirements for immune cell activation
by TDM-mimetics are not well understood and the situation is
further complicated by the presence of additional receptors
for TDM, such as MCL, which directly impact the expression
of mincle.11 At the cytokine level, TDM-analogs with simple
saturated ester groups display disparate behaviour and seem to
show maximum activation with intermediate length chains.12
Due to the highly amphiphilic nature of these compounds, solu-
bility issues are unavoidable and may complicate interpretation
of some experiments. Our discovery that phenol-containing
esters, like brartemicin, are strong binders of mincle CRD that
are soluble at millimolar concentrations in aqueous media, will
enable the preparation of new classes of soluble TDM analogs
that may help shed light on the mechanism involved in
immune cell activation through the mincle pathway.
1
(CAM-stain)). H NMR (400 MHz, CDCl3) δ 7.39–7.14 (m, 50H),
6.36 (d, J = 1.8 Hz, 2H), 6.31 (d, J = 1.8 Hz, 2H), 5.10 (d, J =
3.5 Hz, 2H), 5.02–4.92 (m, 12H), 4.83–4.74 (m, 4H), 4.57–4.48
(m, 8H), 4.26 (d, J = 10.2 Hz, 4H), 4.00 (t, J = 9.6 Hz, 2H), 3.59
(t, J = 9.6 Hz, 2H), 3.43 (dd, J = 3.5, 9.6 Hz, 2H), 2.24 (s, 6H).
13C NMR (100 MHz, CDCl3) δ 168.1, 160.4, 157.2, 138.9, 138.4,
138.2, 138.0, 136.7, 136.6, 128.7, 128.6, 128.5, 128.4, 128.4,
128.2, 128.2, 127.9, 127.8, 127.7, 127.6, 127.5, 126.8, 117.2,
108.2, 98.5, 93.7, 81.5, 79.2, 77.9, 75.5, 75.3, 72.6, 70.1, 69.4,
63.2, 20.1. IR (neat) νmax/cm−1 3031, 2926, 2864, 1725, 1602,
1586, 1497, 1453, 1263, 1157, 1089, 1070, 995, 733, 698. [α]D26.8
=
+55.2 (c 0.50, CHCl3).
6,6′-Bis-IJ2,4-dihydroxy-6-methylbenzoate)-α,α-trehalose (1).
The benzyl-protected brartemicin (33.1 mg, 21.4 μmol, 1.0
equiv.) was dissolved in MeOH/CHCl3 1 : 1 (5 mL) in a 50 mL
round-bottom flask and the flask was then purged with
argon. To the solution was added PdIJOH)2/C (23 mg, 20%,
32 μmol, 1.5 equiv.) and the mixture was stirred while
flushed with argon. The atmosphere in the flask was subse-
quently saturated with H2-gas from a balloon. After 6 h the
reaction had run to completion as judged by TLC and the
mixture was filtered to remove residues of the catalyst. The
solvents were removed in vacuo to yield brartemicin (1) as an
analytically pure off-white solid (13.5 mg, 21.0 μmol, 98%).
The product was purified further by semi-preparative C-18 RP
HPLC prior to binding assays (5% → 70% MeOH in H2O over
17 min, hold 3 min, then 70% → 100% MeOH, hold 1 min,
10 mL min−1, RT = 16.7 min, Phenomenex Luna 5u C18(2)
100 A, New Column, 250 × 10 mm). Rf 0.58 (EtOAc/MeOH/
1
H2O 4 : 1 : 1 (CAM-stain)). H NMR (400 MHz, CD3OD) δ 6.21
(d, J = 2.3 Hz, 2H), 6.15 (d, J = 2.3 Hz, 2H), 5.13 (d, J = 3.7 Hz,
2H), 4.58 (dd, J = 2.0, 12.0 Hz, 2H), 4.46 (dd, J = 4.9, 12.0 Hz,
2H), 4.21–4.17 (m, 2H), 3.83 (t, J = 9.6 Hz, 2H), 3.49 (dd, J =
3.7, 9.6 Hz, 2H), 3.43 (t, J = 9.6 Hz, 2H) 2.51 (s, 6H). 13C NMR
(100 MHz, CD3OD) δ 172.8, 166.3, 163.9, 144.9, 112.5, 105.6,
101.7, 95.6, 74.5, 73.2, 72.2, 71.3, 65.4, 24.9. HRMS IJm/z):
[M–H]− calcd for C28H33O17, 641.1723; found, 641.1723. IR
(neat) νmax/cm−1 3292, 2928, 2856, 1644, 1617, 1447, 1312,
1256. [α]2D6.5 = +78.8 (c 0.50, MeOH).
Experimental
Synthesis
2,3,4,2′,3′,4′-Hexa-IJbenzyloxy)-6,6′-bis-IJ2,4-bis-IJbenzyloxy)-6-
methylbenzoate)-α,α-trehalose. An azeotrope was formed with
2,3,4,2′,3′,4′-Hexa-IJbenzyloxy)-6,6′-bis-IJ2,4-bis-IJbenzyloxy)-6-
methylbenzoate)-α,β-trehalose. The hexabenzylated α,β-trehalose
Med. Chem. Commun.
This journal is © The Royal Society of Chemistry 2015